UBC Faculty Research and Publications

Are antidepressants safe in pregnancy? A focus on SSRIs Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 76 reviews the harms and benefits of selective serotonin reuptake inhibitors (SSRIs) in pregnancy. Conclusions and clinical implications: There is no evidence that SSRIs in pregnancy improve maternal or infant health, and substantive evidence that they pose a risk to the fetus. Thus the harms exceed the benefits in this setting. Non-drug options such as cognitive behavioural therapy or psychotherapy are also unproven, but do not carry a risk to the fetus. The common argument of their lack of availability is not relevant for this relatively small, high priority population. If a patient wants to stop SSRIs in pregnancy, it is best to taper the dose over at least 1 week to minimize withdrawal symptoms. Exercise, social support, sleep hygiene and good nutrition are important for all pregnant people, including those with symptoms of depression.

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International